Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Dynavax Technologies Corporation

$15.5

+0.01 (+0.06%)

Last traded Feb 9, 2026. This price is not current.

C 43Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.82 B
EPS
-0.33
P/E Ratio
-
Value Trade
110.13 M
0.13 %
Week
0.52 %
1 Month
40.27 %
3 Month
45.54 %
6 Month
44.86 %
5 Year
-81.87 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
7.11 M
52 Week Range
9.20 - 15.73
% held by Insiders
0.81 %
% held by Institutions
97.03 %
Enterprise Value
1.46 B
Total Shares
117.28 M
Short %
8.69 %
Float Shares
112.71 M
Company Description
Founded:1996

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 data readout example
Phase 1/2
—

Subscribe to access the data.

Vaccines
Infectious Diseases
Phase 1/2
—

Subscribe to access the data.

Vaccines
Infectious Diseases
Phase 1/2
—

Subscribe to access the data.

Vaccines
Infectious Diseases
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-05-01
HEPLISAV-B (four-dose regimen) sBLA
PDUFA Date
PDUFA
CRL
–
–
–
2024-05-01
HEPLISAV-B (four-dose regimen) sBLA
PDUFA Date
PDUFA
CRL
–
–
–
2024-05-01
HEPLISAV-B (four-dose regimen) sBLA
PDUFA Date
PDUFA
CRL
–
–
–
Unlock 2 more historical catalysts
Drug Pipeline Intelligence
C43
Pipeline Score
$156M
Pipeline Value
$800M
Commercial Value
Overvalued
Valuation Signal
5
Drugs Scored
0.2x
rNPV / MCap
Dynavax Technologies Corporation carries a moderate pipeline score (43/100), with $390M risk-adjusted pipeline value, led by 3M-052-AF in HIV Infections (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Sep 2025; product lines from the latest annual filing)Revenue $330.5M x 2.4 = $800M
ProductRevenuePrior periodChange
HEPLISAV-B$268M$213M+25.8%
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
3M-052-AF
Monoclonal antibody
Completed		HIV InfectionsPhase 1NCT0417735522% $153M COMPLETED 127 - -Nov 4, 2024 -Sep 2, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Z-1018
shingles
Phase 1/2
2025-10-21

Part 1 of the Phase 1/2 trial demonstrated favorable safety and immunogenicity profiles.

Read More

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

Read More
Z-1018
shingles
Phase 1/2
2025-10-21

Part 1 of the Phase 1/2 trial demonstrated favorable safety and immunogenicity profiles.

Read More

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

Read More
Z-1018
shingles
Phase 1/2
2025-10-21

Part 1 of the Phase 1/2 trial demonstrated favorable safety and immunogenicity profiles.

Read More

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH $1.8M IN THE LAST 3 MONTHS
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in DVAX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
DVAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How DVAX ranks across every disease it competes in
Competitive Position is a premium feature
See how DVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial